Gold Standard Diagnostics (GSD) has extended its relationship with Fujirebio Diagnostics for the distribution of its Cyfra 21-1 EIA assays in the US.
Fujirebio provides in vitro diagnostics, and biomarkers and is mailnly focused on oncology markers.
The Cyfra 21-1 EIA kit is used to quantitatively determine soluble cytokeratin 19 fragments in human serum.
Cyfra 21-1 EIA kit is also used to monitor disease progression during the course of disease and treatment in patients with lung cancer.
David Grenache, a medical director at Arup Laboratories, said FDA clearance of Cyfra 21-1 allows laboratories in the US the opportunity to provide a valuable diagnostic tool to oncologists in the management of lung cancer.
GSD also distributes Fujirebio’s HE4 EIA, Multi-Constituent Tumor Marker control and Vitamin D control.